Free cash flow
United Therapeutics Free cash flow increased by 109.2% to $362.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.2%, from $386.30M to $362.50M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 21.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Detailed definition
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Peer comparison
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flowHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $131.90M | $162.30M | $104.00M | $275.20M | $110.00M | $189.80M | $88.70M | $333.50M | $61.60M | $280.50M | $72.00M | $338.30M | $187.10M | $300.70M | $254.50M | $386.30M | $129.50M | $351.60M | $173.30M | $362.50M |
| QoQ Change | — | +23.0% | -35.9% | +164.6% | -60.0% | +72.5% | -53.3% | +276.0% | -81.5% | +355.4% | -74.3% | +369.9% | -44.7% | +60.7% | -15.4% | +51.8% | -66.5% | +171.5% | -50.7% | +109.2% |
| YoY Change | — | — | — | — | -16.6% | +16.9% | -14.7% | +21.2% | -44.0% | +47.8% | -18.8% | +1.4% | +203.7% | +7.2% | +253.5% | +14.2% | -30.8% | +16.9% | -31.9% | -6.2% |
Free cash flow at Other Companies
Frequently Asked Questions
- What is United Therapeutics's free cash flow?
- United Therapeutics (UTHR) reported free cash flow of $362.50M in Q1 2026.
- How has United Therapeutics's free cash flow changed year-over-year?
- United Therapeutics's free cash flow decreased by 6.2% year-over-year, from $386.30M to $362.50M.
- What is the long-term trend for United Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), United Therapeutics's free cash flow has grown at a 21.5% compound annual growth rate (CAGR), from $477.40M to $1.04B.
- What does free cash flow mean?
- The cash remaining after a company pays for its operating expenses and capital investments.